BRPI0519044B8 - anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso - Google Patents

anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso

Info

Publication number
BRPI0519044B8
BRPI0519044B8 BRPI0519044A BRPI0519044A BRPI0519044B8 BR PI0519044 B8 BRPI0519044 B8 BR PI0519044B8 BR PI0519044 A BRPI0519044 A BR PI0519044A BR PI0519044 A BRPI0519044 A BR PI0519044A BR PI0519044 B8 BRPI0519044 B8 BR PI0519044B8
Authority
BR
Brazil
Prior art keywords
directed against
antibody
antibody directed
antigen
monoclonal antibody
Prior art date
Application number
BRPI0519044A
Other languages
English (en)
Portuguese (pt)
Inventor
Gaucher Christine
De Romeuf Christophe
Prost Jean-François
Teillaud Jean-Luc
Original Assignee
Lab Francais Du Fractionnement
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement, Lfb Biotechnologies filed Critical Lab Francais Du Fractionnement
Publication of BRPI0519044A2 publication Critical patent/BRPI0519044A2/pt
Publication of BRPI0519044B1 publication Critical patent/BRPI0519044B1/pt
Publication of BRPI0519044B8 publication Critical patent/BRPI0519044B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0519044A 2004-12-15 2005-12-14 anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso BRPI0519044B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0413320 2004-12-15
FR0413320A FR2879204B1 (fr) 2004-12-15 2004-12-15 Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
PCT/FR2005/003123 WO2006064121A2 (fr) 2004-12-15 2005-12-14 Anticorps cytotoxique dirige contre les proliferations hematopoïetiques lymphoïdes de type b

Publications (3)

Publication Number Publication Date
BRPI0519044A2 BRPI0519044A2 (pt) 2008-12-23
BRPI0519044B1 BRPI0519044B1 (pt) 2020-11-17
BRPI0519044B8 true BRPI0519044B8 (pt) 2021-05-25

Family

ID=34953790

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519044A BRPI0519044B8 (pt) 2004-12-15 2005-12-14 anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso

Country Status (16)

Country Link
US (2) US9234045B2 (enExample)
EP (2) EP1824887B1 (enExample)
JP (2) JP4999699B2 (enExample)
KR (3) KR20120023177A (enExample)
CN (1) CN101115772B (enExample)
AU (1) AU2005315534B2 (enExample)
BE (1) BE2023C542I2 (enExample)
BR (1) BRPI0519044B8 (enExample)
CA (1) CA2590303C (enExample)
DK (1) DK1824887T3 (enExample)
ES (1) ES2588161T3 (enExample)
FR (2) FR2879204B1 (enExample)
IL (1) IL183947A0 (enExample)
NL (1) NL301242I2 (enExample)
PL (1) PL1824887T3 (enExample)
WO (1) WO2006064121A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
FR2879605B1 (fr) * 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
EP2946810A1 (en) 2005-02-03 2015-11-25 TopoTarget UK Limited Combination therapy using an HDAC inhibitor and Vincristine for treating cancer
CN102579417B (zh) 2005-05-13 2014-11-26 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
EP2361619A1 (en) 2005-11-10 2011-08-31 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1985633A1 (en) * 2007-04-26 2008-10-29 LFB Biotechnologies Kit of parts for the treatment of cancer or infectious diseases
CA2700173C (en) 2007-09-25 2016-10-11 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
FR2940616A1 (fr) * 2008-12-30 2010-07-02 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome primaire intraoculaire.
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
FR2962908A1 (fr) * 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
FR2966043A1 (fr) * 2010-10-14 2012-04-20 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome cerebral primitif
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
US20150290244A1 (en) * 2012-07-13 2015-10-15 The Trustees Of The University Of Pennsylvania Use of cart19 to deplete normal b cells to induce tolerance
EP3756686A1 (en) * 2012-11-02 2020-12-30 TG Therapeutics Inc. Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
EA201892284A1 (ru) 2016-05-27 2019-08-30 Тг Терапьютикс, Инк. Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
AU2017322501A1 (en) 2016-09-09 2019-03-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of an anti-CD20 antibody, PI3 kinase-delta inhibitor, and anti-PD-1 or anti-PD-L1 antibody for treating hematological cancers
WO2022104150A1 (en) 2020-11-12 2022-05-19 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
WO2025199155A1 (en) * 2024-03-18 2025-09-25 Tg Therapeutics, Inc. Subcutaneous formulations of anti-cd20 antibody

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
BR9808584A (pt) * 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
FR2844455B1 (fr) 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
US7595165B2 (en) 2002-09-13 2009-09-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Method of measuring activation of effector cells
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1944320A1 (en) * 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
CN1542132A (zh) * 2003-04-30 2004-11-03 上海新霁生物科技有限公司 高效表达治疗肿瘤并含有人恒定区全抗体基因的重组病毒及其用途
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.

Also Published As

Publication number Publication date
JP2012126724A (ja) 2012-07-05
KR101340192B1 (ko) 2013-12-12
FR2879204A1 (fr) 2006-06-16
NL301242I2 (nl) 2023-11-01
JP2008523793A (ja) 2008-07-10
CN101115772B (zh) 2012-10-17
FR23C1038I2 (fr) 2024-05-03
BE2023C542I2 (enExample) 2025-02-07
KR101418695B1 (ko) 2014-07-10
US20090053233A1 (en) 2009-02-26
IL183947A0 (en) 2007-10-31
WO2006064121A2 (fr) 2006-06-22
US9873745B2 (en) 2018-01-23
CN101115772A (zh) 2008-01-30
BRPI0519044A2 (pt) 2008-12-23
KR20120023177A (ko) 2012-03-12
EP2949674A1 (fr) 2015-12-02
PL1824887T3 (pl) 2016-12-30
ES2588161T3 (es) 2016-10-31
CA2590303A1 (fr) 2006-06-22
JP5693440B2 (ja) 2015-04-01
WO2006064121A3 (fr) 2006-08-31
CA2590303C (fr) 2015-05-26
BRPI0519044B1 (pt) 2020-11-17
EP1824887B1 (fr) 2016-05-25
NL301242I1 (nl) 2023-09-20
EP1824887A2 (fr) 2007-08-29
DK1824887T3 (en) 2016-09-05
AU2005315534B2 (en) 2011-11-10
FR23C1038I1 (fr) 2023-12-08
JP4999699B2 (ja) 2012-08-15
FR2879204B1 (fr) 2007-02-16
US9234045B2 (en) 2016-01-12
KR20140003660A (ko) 2014-01-09
AU2005315534A1 (en) 2006-06-22
KR20070102513A (ko) 2007-10-18
US20160060350A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
BRPI0519044A2 (pt) anticorpo citotàxico direcionado contra proliferaÇÕes hematopoÉticas linfàides do tipo b
BR112022009679A2 (pt) Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
PH12020500078A1 (en) Anti-ctla-4 antibodies and uses thereof
MX2009004665A (es) Anticuerpos de anti-factor d humanizado.
CY1120018T1 (el) Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
CY1123534T1 (el) Αντισωματα που περιλαμβανουν τροποποιημενες βαριες σταθερες περιοχες
EA202092945A1 (ru) Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии
CY1116982T1 (el) Ανθρωποποιημενα αντισωματα αντι-παραγοντα d και χρησεις αυτων
WO2010076400A8 (fr) Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome intraoculaire primitif
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
MA45976B1 (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant
MX2020001873A (es) Agentes de union.
HK1254861A1 (zh) 抗lag3抗体及其用途
RU2019119442A (ru) Новый коньюгат аманитина
SA520420332B1 (ar) الأجسام المضادة لمكون مضاد للمتمم وطرق استخدامها
BR0110927A (pt) Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
CY1112953T1 (el) Χρηση των αντι-cd100 αντισωματων
PE20200927A1 (es) Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas
CO6180445A2 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
HN2004000356A (es) Anticuerpos dirigidos a m-csf
AR028927A1 (es) Anticuerpo monoclonal humano contra la molecula co-estimuladora ailim transductora de senales y uso farmaceutico del mismo
MA43773B1 (fr) Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
BR112022019060A2 (pt) Células neurais hipoimunogênicas para o tratamento de distúrbios e condições neurológicas
BR112021011729A2 (pt) Tubulisinas e conjugados de proteína-tubulisina
CY1126559T1 (el) Παραδειγμα θεραπειας για θεραπεια συνδυασμου anti-cd19 αντισωματος και βενετοκλαξης

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LFB BIOTECHNOLOGIES (FR)

Free format text: TRANSFERIDO DE: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOT

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (FR)